SWEDISH ORPHAN Aktie

>SWEDISH ORPHAN Aktienkurs

36.54 EUR -2.5% (TradegateBSX)

Ask: 37.36 EUR / 30 Stück

Bid: 36.98 EUR / 30 Stück

Tagesumsatz: 66 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>SWEDISH ORPHAN Performance

1 Woche: +2,8%

1 Monat: +2,1%

3 Monate: +18,1%

6 Monate: +30,0%

1 Jahr: +39,3%

laufendes Jahr: +18,9%

>SWEDISH ORPHAN Aktie

Name:

SWEDISH ORPHAN BIOVITRUM

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0000872095 / A0LA5K

Symbol/ Ticker:

B6E (Frankfurt)

Kürzel:

FRA:B6E, ETR:B6E, B6E:GR

Index:

Webseite:

https://www.sobi.com/

Profil:

Swedish Orphan Biovitrum AB is an international biopharmaceutical company headquartered in Stockholm, Sweden, specializing in treatments for rare diseases within haematology, immunology, and specialty care. It focuses on researching, developing, manu..
>Volltext..

Marktkapitalisierung:

12884 Mio. EUR

Unternehmenswert:

13847.18 Mio. EUR

Umsatz:

2646.8 Mio. EUR

EBITDA:

1700.64 Mio. EUR

Nettogewinn:

44.81 Mio. EUR

Gewinn je Aktie:

0.13 EUR

Schulden:

1077.49 Mio. EUR

Liquide Mittel:

97.58 Mio. EUR

Operativer Cashflow:

802.75 Mio. EUR

Bargeldquote:

0.06

Umsatzwachstum:

14.96%

Gewinnwachstum:

-86.96%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SWEDISH ORPHAN

Letzte Datenerhebung:

04.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 345.66 Mio. St.

Frei handelbar: 52%

Leerverk. Aktien: -

Rückkaufquote: -0.18%

Mitarbeiter: 1888

Umsatz/Mitarb.: 1.4 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 16.6%

Bewertung:

KGV: 307.54

KGV lG: 23.37

KUV: 4.8

KBV: 3.65

PEG-Ratio: -

EV/EBITDA: 8.14

Rentabilität:

Bruttomarge: 43.63%

Gewinnmarge: 1.69%

Operative Marge: 28.5%

Managementeffizenz:

Gesamtkaprendite: 0.67%

Eigenkaprendite: 1.23%

>Peer Group

Gesundheit

>SWEDISH ORPHAN Chart & Kurs - Tradegate

>SWEDISH ORPHAN News

31.03.26 - 13:06	Sobi publishes Annual and Sustainability Report for 2025 (PR Newswire)
	STOCKHOLM, March 31, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for 2025, outlining the company's progress in unlocking the potential of breakthrough innovations and therapies for people living with rare diseases.......

31.03.26 - 11:00

Sobi publishes Annual and Sustainability Report for 2025 (Cision)

Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for 2025, outlining the company's progress in unlocking the potential of breakthrough innovations and therapies for people living with rare diseases. Sobi has a strong focus on building a sustainable business through collaboration and scientific expertise, ensuring that everyone eligible within its therapeutic areas has access to approved medicines. In 2025, over 53,000 full-time equivalent patients were treated with a Sobi medicine, delivering on Sobi's mission to deliver therapies for people...

27.03.26 - 09:00	Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) (PR Newswire)
	STOCKHOLM, March 27, 2026 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Wednesday, 6 May 2026 at 10.00 at IVA Konferenscenter, Grev Turegatan 16,......

18.02.26 - 09:30	Sobi Targets SEK 55 Bln Revenue By 2030 (AFX)
	STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY) on Wednesday said it is hosting its Capital Markets Day, today, where the biopharma company plans to outline a new mid-term ambition to re......

11.02.26 - 13:27	Sobi to host a Capital Markets Day on 18 February 2026 (PR Newswire)
	STOCKHOLM, Feb. 11, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person in Stockholm, Sweden, on 18 February 2026, starting at 13:00 CET. A live webcast will......

09.02.26 - 15:51	Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout (PR Newswire)
	STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) Sobi® (STO: SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of Arthrosi by Sobi. Upon completion of the transaction, Sobi has acquired all outstanding shares of......

05.02.26 - 12:42	Swedish Orphan Biovitrum AB reports Q4 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 09:00	Swedish Orphan Biovitrum AB Profit Rises In Q4 (AFX)
	STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY) announced earnings for its fourth quarter that Increases, from the same period last yearThe company's bottom line totaled SEK1.861 billion......

05.02.26 - 08:30	Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress (PR Newswire)
	STOCKHOLM, Feb. 5, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2025. Fourth Quarter 2025 Total revenue increased 5 per cent, 16 per cent at CER1, to SEK 7,821 M (7,436) Haematology revenue increased 25......

05.02.26 - 08:27	Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress (PR Newswire)
	STOCKHOLM, Feb. 5, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2025. Fourth Quarter 2025 Total revenue increased 5 per cent, 16 per cent at CER1, to SEK 7,821 M (7,436) Haematology revenue increased 25......

03.02.26 - 10:12	Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026 (PR Newswire)
	STOCKHOLM, Feb. 3, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced its participation at the 19th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), taking place 3-6 February 2026 in Dublin, Ireland. At this......

15.01.26 - 14:01	SOBI: 2025 Revenue, Adj. EBITA Margin Higher Than Prior Guidance (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST) announced that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year reve......

15.01.26 - 13:15	Sobi′s 2025 annual revenue and adjusted EBITA margin exceed previous outlook (PR Newswire)
	STOCKHOLM, Jan. 15, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was approximately SEK 28.2 B, representing approximately 15......

15.01.26 - 13:06	Sobi′s 2025 annual revenue and adjusted EBITA margin exceed previous outlook (PR Newswire)
	STOCKHOLM, Jan. 15, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was approximately SEK 28.2 B, representing approximately 15......

08.01.26 - 04:54	Sobi Reports Positive Phase 2a EMBRACE Study Results For Gamifant In IFN?-Driven Sepsis (AFX)
	STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (publ) (SOBI.ST) or Sobi announced topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-dr......

18.12.25 - 11:24	Save the Date: Sobi to host a Capital Markets Day on 18 February 2026 (PR Newswire)
	STOCKHOLM, Dec. 18, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person in Stockholm, Sweden, on 18 February 2026, starting at 13:00 CET. A live webcast will......

15.12.25 - 08:00	Sobi To Acquire Arthrosi Therapeutics (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST) has entered into an acquisition agreement with Arthrosi Therapeutics, which was invested in and incubated by Viva Biotech......

15.12.25 - 07:30	Viva Biotech′s invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. (PR Newswire)
	STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will......

15.12.25 - 07:09	Viva Biotech′s invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. (PR Newswire)
	STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will......

23.10.25 - 16:12	Swedish Orphan Biovitrum AB reports Q3 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram